Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  McKesson Corporation    MCK

MCKESSON CORPORATION

(MCK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

McKesson : to Present at the 38th Annual J.P. Morgan Healthcare Conference Will Provide Company Overview and Review Updated Financial Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
01/14/2020 | 08:51am EST

IRVING - McKesson Corporation (NYSE: MCK) will present at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco tomorrow, January 14, 2020 at 9:00 AM PT (12:00 PM ET).

Brian Tyler, chief executive officer of McKesson, will provide a company overview and review topics including: McKesson's strategic growth initiatives

McKesson's differentiated specialty portfolio

Company innovation such as the recent launch of AMP: Access for More Patients

Overview of McKesson's capital allocation approach

Updated Fiscal 2020 Adjusted Earnings per diluted share outlook: the company now anticipates Adjusted Earnings per diluted share of $14.60 to $14.80 for full-year fiscal 2020, an increase from the previous range of $14.00 to $14.60.

'The focus on executing against our strategic growth initiatives and disciplined capital allocation is reflected in our updated outlook for fiscal 2020. Our businesses are well positioned to continue to deliver growth,' said Brian Tyler, chief executive officer. 'Based on the continued momentum and trends in our business, we have narrowed and raised our Adjusted EPS guidance range for fiscal 2020.'

The live audio webcasts for the J.P. Morgan Healthcare conference will be available on McKesson's Investor Relations website at http://investor.mckesson.com. McKesson will host a conference call at 8:00 AM ET on February 4, 2020 to discuss third quarter fiscal 2020 financial results. A live audio webcast of the conference call will be available on McKesson's Investor Relations website, along with the company's earnings press release, financial tables and slide presentation. The conference call can also be accessed by dialing 786-815-8297. The password is 'McKesson'.

Adjusted Earnings

McKesson separately reports financial results on the basis of Adjusted Earnings. Adjusted Earnings is a non-GAAP financial measure defined as GAAP income/loss from continuing operations, excluding amortization of acquisition-related intangible assets, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment and related charges, and other adjustments as well as the related income tax effects for each of these items, as applicable.

The company does not provide forward-looking guidance on a GAAP basis prospectively as McKesson is unable to provide a quantitative reconciliation of this forward-looking non-GAAP measure to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because McKesson cannot reliably forecast LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are inherently uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.

Cautionary Statements

Except for historical information contained in this press release, matters discussed may constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements. Forward-looking statements may be identified by their use of terminology such as 'believes', 'expects', 'anticipates', 'may', 'will', 'should', 'seeks', 'approximately', 'intends', 'plans', 'estimates' or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans, assumptions or intentions may also include forward-looking statements. We encourage investors to read the important risk factors described in the company's Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission. These risk factors include, but are not limited to: changes in the healthcare industry and regulatory environment; fluctuations in foreign currency exchange rates; the impact of the Change Healthcare joint venture on the company's results of operations; the company's ability to manage and complete divestitures and distributions; material adverse resolution of pending legal proceedings, including those related to the distribution of controlled substances; cyberattack, natural disaster, or malfunction of sophisticated internal computer systems to perform as designed and the potential inadequacy of insurance to cover property loss or liability claims.

About McKesson Corporation

McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, healthcare technology, community oncology and specialty care. McKesson partners with life sciences companies, manufacturers, providers, pharmacies, governments and other healthcare organizations to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities to improve patient care in every setting - one product, one partner, one patient at a time. McKesson has been named a 'Most Admired Company' in the healthcare wholesaler category by FORTUNE, a 'Best Place to Work' by the Human Rights Campaign Foundation, and a top vmilitary-friendly company by Military Friendly.

Contact:

Holly Weiss

Tel: 972-969-9174

Email: Holly.Weiss@McKesson.com

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MCKESSON CORPORATION
03:18pOpioid companies say lawyers' fee demand threatens settlement talks
RE
02/25Mallinckrodt Nets Government Support for $1.6 Billion Opioid Deal -- 3rd Upda..
DJ
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/10MCKESSON CORP : Entry into a Material Definitive Agreement, Other Events, Financ..
AQ
02/10MCKESSON : Launches Exchange Offer to Split-Off Its Interest in Change Healthcar..
BU
02/04MCKESSON : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
02/04MCKESSON : Revenue Misses Expectations, Adjusted Earnings Beat
DJ
More news
Financials (USD)
Sales 2020 228 B
EBIT 2020 3 786 M
Net income 2020 474 M
Debt 2020 4 732 M
Yield 2020 1,10%
P/E ratio 2020 56,6x
P/E ratio 2021 11,5x
EV / Sales2020 0,14x
EV / Sales2021 0,13x
Capitalization 26 157 M
Chart MCKESSON CORPORATION
Duration : Period :
McKesson Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MCKESSON CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 167,94  $
Last Close Price 147,71  $
Spread / Highest target 33,4%
Spread / Average Target 13,7%
Spread / Lowest Target -5,22%
EPS Revisions
Managers
NameTitle
Brian Scott Tyler Chief Executive Officer & Director
Edward A. Mueller Chairman
Britt Vitalone Chief Financial Officer & Executive Vice President
Nancy Flores EVP, Chief Technology & Information Officer
M. Christine Jacobs Independent Director
Sector and Competitors